Imunocare

About Imunocare

Shanghai Immunocan Biotech Co., Ltd., founded in 2020, is a biotechnology firm that develops genetically engineered animal models for therapeutic antibody discovery. The company focuses on creating platforms to accelerate the development of safer and more effective treatments for human diseases. In May 2026, Immunocan announced the completion of a 250 million yuan Series A financing round to advance its platform research and development, commercialization, and the establishment of an AI drug screening platform. The company's core technological advantage lies in its proprietary MASIRT® (Massive-fragment Across Species In situ Replacement Technology). This gene-editing technology enables the in-situ replacement of megabase-scale gene fragments in a single operation, a significant breakthrough that allows for the rapid construction of complex animal models. It facilitates the transfer of genes between species, such as replacing the immunoglobulin genes in mice or rabbits with their human counterparts, to produce fully human antibodies directly from an animal's immune response. Imunocan's primary offerings are its specialized antibody discovery platforms. The ImmuMab® mouse is a key platform that generates fully human antibodies, designed to have lower immunogenicity and reduce the need for subsequent humanization processes. The company has also launched the ImmuAlpaca® mouse, an innovative platform that produces alpaca-derived heavy-chain-only antibodies, also known as nanobodies. These small antibody fragments offer flexibility for creating novel therapeutic molecules. The firm is expanding its portfolio with platforms currently under construction, including a model for generating fully human antibodies in rabbits. Imunocan operates on a business model centered around partnering with global pharmaceutical and biotechnology companies. It provides access to its innovative discovery platforms to support the development of various drug modalities, including monoclonal antibodies, ADCs, and cell therapies. The company is also integrating artificial intelligence into its workflow, developing the MabAI® antibody discovery platform to analyze the vast amount of sequence data generated from its models and improve screening efficiency and drug candidate viability.